MBR’s micro-Clastogenicity Screen

MBR’s micro-clastogenicity screen  is ideal for predicting the Regulatory Chromosome Aberration Test.  Screening for potential mutagencity in bacteria is the first step in determining a drug’s genotoxicity potential.  The second step is to test the compound’s clastogenic effects in a mammalian system.  There are two such assays – an in vitro chromosome aberration test and an in vivo micronucleus assay – both of which test for chromosomal damage with the latter also detecting aneugens. 

MBR offers a micro-clastogenicity screen that is an excellent predictor of the regulatory ICH-compliant in vitro mammalian chromosome aberration assay and identifies compounds that are aneugenic.  The screen detects clastogenicity (chromosomal aberrations) via the presence of chromatin in micronuclei formed during cell division.  MBR’s micronized version also measures cytotoxicity per current OECD guidelines for the in vitro micronucleus assay. Comparison of MBR’s micro-clastogenicity screen data with the classical chromosome aberration test indicates that this screen predicts chromosome aberrations as well as the OECD in vitro micronuclei assay (85-95% predictive). 

Like our microAmes screen, our micro-clastogenicity screen is a rapid, accurate, and cost-effective alternative to the regulatory version.  Our genotoxicity experts are trained and experienced in both screening and regulatory chromosome aberration assays, and in applying this technology to lead optimization.